Kimberly A. Foster
Kimberly A. Foster has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Carrie Cummings
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington
12 shared publications - David Wu
Department of Pathology and Laboratory Medicine, University of Washington, Seattle, WA
12 shared publications - Derek L. Stirewalt
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington
12 shared publications - H. Joachim Deeg
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA
12 shared publications - Jessica Lok
Translational Science and Therapeutics Division, Fred Hutchinson Cancer Center, Seattle, Washington
12 shared publications - Laura D. Baquero Galvis
Institute for Stem Cell and Regenerative Medicine, University of Washington, Seattle, Washington
12 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Data from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
Acquired mutations in spliceosome genes in early hematopoietic stem/progenitor cells are common events in myelodysplastic neoplasms (MDS) and related myeloid malignancies. Mutations in the spliceosome factor subunit B1 (SF3B1) gene occur in ≥20% of MDS cases at conserved hotspots and in early neoplastic clones as driver events. Neoantigens from aberrant SF3B1 proteins could serve as shared T-cell therapy targets for SF3B1-mutated myeloid neoplasms. We identified a candidate neoantigen from the prevalent SF3B1K700E variant using in silico predictions of epitope processing and presentation and then validated presentation and immunogenicity in vitro. CD8+ T cells recognizing SF3B1K700E demonstrated high functional avidity and killed neoplastic myeloid cell lines and primary cells in an antigen-specific manner. We then sequenced, cloned, and transduced an SF3B1K700E-specific T-cell receptor into third-party T cells and confirmed that T-cell receptor transfer conferred antigen specificity and killing of neoplastic myeloid cells in vitro and in vivo. The data indicate that the SF3B1K700E neoantigen represents a promising T-cell target for patients with SF3B1-mutated MDS and acute myeloid leukemia.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
Acquired mutations in spliceosome genes in early hematopoietic stem/progenitor cells are common events in myelodysplastic neoplasms (MDS) and related myeloid malignancies. Mutations in the spliceosome factor subunit B1 (SF3B1) gene occur in ≥20% of MDS cases at conserved hotspots and in early neoplastic clones as driver events. Neoantigens from aberrant SF3B1 proteins could serve as shared T-cell therapy targets for SF3B1-mutated myeloid neoplasms. We identified a candidate neoantigen from the prevalent SF3B1K700E variant using in silico predictions of epitope processing and presentation and then validated presentation and immunogenicity in vitro. CD8+ T cells recognizing SF3B1K700E demonstrated high functional avidity and killed neoplastic myeloid cell lines and primary cells in an antigen-specific manner. We then sequenced, cloned, and transduced an SF3B1K700E-specific T-cell receptor into third-party T cells and confirmed that T-cell receptor transfer conferred antigen specificity and killing of neoplastic myeloid cells in vitro and in vivo. The data indicate that the SF3B1K700E neoantigen represents a promising T-cell target for patients with SF3B1-mutated MDS and acute myeloid leukemia.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms